{
    "Trade/Device Name(s)": [
        "Solana Influenza A + B Assay"
    ],
    "Submitter Information": "Quidel Corporation",
    "510(k) Number": "K161814",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131728"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OCC",
        "OZE"
    ],
    "Summary Letter Date": "September 27, 2016",
    "Summary Letter Received Date": "July 1, 2016",
    "Submission Date": "June 30, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.3980"
    ],
    "Regulation Name(s)": [
        "Respiratory viral panel multiplex nucleic acid assay"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Influenza A viral RNA",
        "Influenza B viral RNA"
    ],
    "Specimen Type(s)": [
        "Nasal swab",
        "Nasopharyngeal swab"
    ],
    "Specimen Container(s)": [
        "Viral transport media",
        "Process Buffer Tube",
        "Reaction Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Solana instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA)",
        "Isothermal amplification",
        "Fluorescent probe detection"
    ],
    "Methodologies": [
        "Molecular amplification",
        "RT-HDA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Solana Influenza A + B molecular assay for qualitative detection and differentiation of influenza A and B viral RNA using RT-HDA on the Solana instrument",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test for detection and differentiation of influenza A and B viral RNA in nasal and nasopharyngeal swabs from symptomatic patients, used as an aid in differential diagnosis in conjunction with clinical and epidemiological risk factors",
    "fda_folder": "Microbiology"
}